Objective: To evaluate the feasibility and safety of single port laparoscopic staging operation compared to four-port operation for early-stage endometrial cancer. Methods: Patients with clinical stage IA, IB, grade 1-3 endometrial cancer, patients were randomly assigned to laparo-endoscopic single-site staging surgery (LESS) or conventional four-port laparoscopic staging surgery (CLS). The primary endpoint was to confirm the non-inferiority of LESS staging surgery in the operation time and the number of resected lymph nodes. Non-inferiority has been considered if the LESS group showed a difference in operating time (< 24 min) and the number of resected lymph nodes (< 5.2) within the lower limit of 20% compared to the CLS group. Results: A total of 107 patients were randomly assigned to the LESS group (n=53) and the CLS group (n=54). There were no differences between LESS and CLS groups in clinical factors including age, body mass index (BMI), gravida, menopause, history of abdominal surgery, and predicted stage of the disease. There was no clinically significant difference in total operation time (LESS group vs. CLS group, 154.96±40.81 min vs 158.19±48.77 min, P = 0.712). On average, 4.6 more pelvic lymph nodes were retrieved in CLS group (LESS group vs. CLS group, 17.81±8.73 vs 22.41±10.56, P = 0.016) and this difference was statistically significant. But this did not mean that LESS is inferior to CLS because we assumed that if the average number of resected lymph nodes of LESS is within the lower limit of 20% (5.2 lymph nodes difference), LESS is comparable to CLS. The 5-year disease-free survival rates were 96.2% and 98.1% (P=0.547), and the 5-year overall survival rates were 98.1% and 100.0% (P=0.311), for LESS group and CLS group, respectively. Conclusion: LESS surgical staging was feasible and safe for surgical management of patients with early-stage endometrial cancer. It was comparable to conventional laparoscopic surgical staging in perioperative outcomes and oncologic outcomes.